Results 101 to 110 of about 1,168 (140)
Some of the next articles are maybe not open access.
Experimental and Molecular Therapeutics, 2021
Background: Transcriptional activation of c-MYC through bromodomain and extra-terminal (BET) proteins contributes to the malignant phenotype of OC and TNBC.
S. Lheureux +13 more
semanticscholar +1 more source
Background: Transcriptional activation of c-MYC through bromodomain and extra-terminal (BET) proteins contributes to the malignant phenotype of OC and TNBC.
S. Lheureux +13 more
semanticscholar +1 more source
Abstract 1088: Advancing non-cytotoxic DNMT1-targeting to treat chemorefractory pancreatic cancer
Experimental and Molecular Therapeutics, 2021The key epigenetic regulator DNA methyltransferase 1 (DNMT1) is a scientifically validated target in p53-null chemorefractory cancers like pancreatic ductal adenocarcinoma (PDAC) since DNMT1-depletion effects cancer cell cycle exits by p53-independent ...
R. Tohme +8 more
semanticscholar +1 more source
Experimental and Molecular Therapeutics, 2021
Introduction: Mutations in the RAS family of proto-oncogenes are frequently found in NSCLC, with KRAS being the most prevalent mutated isoform. Of KRAS mutations, the most common is KRAS G12C, representing ~40% of KRAS mutations and occurring in ~13% of ...
B. Ricciuti +17 more
semanticscholar +1 more source
Introduction: Mutations in the RAS family of proto-oncogenes are frequently found in NSCLC, with KRAS being the most prevalent mutated isoform. Of KRAS mutations, the most common is KRAS G12C, representing ~40% of KRAS mutations and occurring in ~13% of ...
B. Ricciuti +17 more
semanticscholar +1 more source
Clinical Trials, 2021
Short title: RTX-240 phase 1 in solid tumorsA phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumorsBackground: T cell checkpoint ...
O. Hamid +6 more
semanticscholar +1 more source
Short title: RTX-240 phase 1 in solid tumorsA phase 1 trial of RTX-240, an allogeneic engineered red blood cell with cell -surface expression of 4-1BBL and trans-presented IL-15, in patients with advanced solid tumorsBackground: T cell checkpoint ...
O. Hamid +6 more
semanticscholar +1 more source
Immunology, 2021
Introduction: A minority of patients (pts) with advanced melanoma achieve long-term survival with immunotherapy and those who relapse following immune checkpoint inhibition (ICI) or BRAFi have limited treatment options.
R. Hawkins +10 more
semanticscholar +1 more source
Introduction: A minority of patients (pts) with advanced melanoma achieve long-term survival with immunotherapy and those who relapse following immune checkpoint inhibition (ICI) or BRAFi have limited treatment options.
R. Hawkins +10 more
semanticscholar +1 more source
VQEG Column: VQEG Meeting Dec. 2021 (Virtual/Online)
ACM SIGMultimedia Records, 2022Welcome to a new column on the ACM SIGMM Records from the Video Quality Experts Group (VQEG).
J. Gutiérrez, Kjell Brunnström
semanticscholar +1 more source
PNH in the Pandemic: New Science and New Treatments in the Spotlight at ASH 2021
Mednet, 2022The 63rd ASH Annual Meeting featured a solid scientific line-up on paroxysmal nocturnal hemoglobinuria (PNH), despite the rarity of the disease, with five events and 23 posters.
Helen Leask
semanticscholar +1 more source
Abstract P3-18-11: Meeting the challenge of successful one-stage lumpectomy for DCIS
Cancer Research, 2022Introduction: Positive lumpectomy margins are associated with an increased risk for ipsilateral tumor recurrence, and necessitate additional procedures to achieve acceptable margins.
Joshua A. Feinberg +7 more
semanticscholar +1 more source
APA Coalition for Psychology in Schools and Education Meeting Minutes, Dec. 3-4, 2021
PsycEXTRA Dataset, 2021semanticscholar +1 more source